YES1 抗体

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Lncap cells, Primary antibody: P03647(YES1  Antibody) at dilution 1/1750, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 10 seconds    

  
  

YES1 antibody targets YES1. a member of the Src family tyrosine kinases (SFKs) involved in cellular signaling pathways regulating proliferation, survival, migration, and differentiation. YES1 is encoded by the YES1 gene located on chromosome 18p11.3 and shares structural homology with other SFKs, including a conserved SH3. SH2. and tyrosine kinase domain. Dysregulation of YES1 is implicated in cancer progression, particularly in tumors with amplified YES1 expression, such as breast, lung, and colorectal cancers. Overexpression correlates with poor prognosis, metastasis, and therapeutic resistance, making YES1 a potential oncogenic driver and therapeutic target.

YES1-specific antibodies are essential tools for studying its expression, activation (via phosphorylation at Tyr426), and interactions in signaling cascades like EGFR, HER2. and integrin pathways. They enable detection in immunohistochemistry (IHC), Western blotting, and flow cytometry, aiding both basic research and clinical diagnostics. Therapeutic antibodies or inhibitors targeting YES1 are under exploration to block its kinase activity or disrupt oncogenic signaling. However, challenges like off-target effects (due to SFK homology) and resistance mechanisms remain. Recent studies highlight YES1's role in tumor microenvironment modulation and immune evasion, expanding its relevance in immunotherapy research. Continued development of high-specificity YES1 antibodies is critical for advancing mechanistic insights and translational applications.